FMS-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in AML. FLT3 is mutated in~30% of patients with AML, either by internal tandem duplications (FLT3-ITD) of the juxta-membrane domain or by a point mutation, usually involving the tyrosine kinase domain. Several FLT3 tyrosine kinase inhibitors are being evaluated in multiple studies aiming at improving outcomes. The most widely used is sorafenib, a potent multikinase inhibitor approved for hepatocellular carcinoma and renal cell carcinoma. Sorafenib monotherapy or in combination with conventional chemotherapy, has been evaluated in various settings in AML, including front-line, relapsed or refractory disease including post-allograft failures and, more recently, as post-transplant maintenance therapy. Encouraging data have emerged with several other agents like lestaurtinib, midostaurin, crenolanib, gilteritinib and quizartinib. Although transient responses to FLT3 inhibitors are often observed in case of disease relapse, the most promising approach is the use of FLT3 inhibitors either in combination with induction chemotherapy or as consolidation/ maintenance therapy after allogeneic hematopoietic cell transplantation. In this review, we summarize the clinical data on sorafenib and other FLT3 inhibitors in AML.
INTRODUCTION

FMS-like tyrosine kinase 3 (FLT3) is mutated in~30% of patients with AML, either by internal tandem duplications (FLT3-ITD) of the juxta-membrane domain, or by a point mutation usually involving the tyrosine kinase domain (FLT3-TKD).
1,2 Both mutations constitutively activate FLT3 in a ligand-independent manner. Patients with AML harboring FLT3-ITD mutations have a high risk of relapse and low cure rates.
3-6 Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended in first CR (CR1) for AML patients harboring this mutation. [7] [8] [9] However, long-term overall survival (OS) remains low, probably due to higher rates of early relapse 10 and poor response to chemotherapy in the salvage setting.
Several small-molecule FLT3 tyrosine kinase inhibitors (TKIs) are being evaluated (Table 1) , namely sorafenib, lestaurtinib (CEP701), midostaurin (PKC412), crenolanib (CP868596), gilteritinib (ASP2215) and quizartinib (AC220). Some studies included AML patients with or without FLT3-ITD or TKD mutations. The efficacy of these agents, as monotherapy or in combination with conventional chemotherapy, has been evaluated in various settings, including front-line, relapsed or refractory disease, including post-allograft failures and, more recently, as maintenance therapy after allo-HCT. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Preliminary results are encouraging, particularly when these TKIs are used in combination with conventional chemotherapy in the induction setting or as maintenance therapy after allo-HCT.
GENETIC CLASSIFICATION OF AML
Treatment strategies for AML patients are dependent on cytogenetic abnormalities. [23] [24] [25] In addition, implications of gene mutations such as NPM1, FLT3 and CEBPα in cytogenetically normal AML are now becoming more established. 26, 27 Currently, AML prognostic subgroups are mostly based on the Medical Research Council and the European LeukemiaNet classifications. 24, 25 The Medical Research Council classification stratifies patients into three major sub-categories based solely on baseline cytogenetics: favorable, intermediate and adverse (Table 2) . 25 The European LeukemiaNet prognostic classification further incorporated recurrent somatic mutations such as NPM1, FLT3 and CEBPα, and proposed four prognostic categories: favorable, intermediate-1, intermediate-2 and adverse (Table 3) . 24 Furthermore, the Cancer Genome Atlas Research Network analyzed the genomic and epigenomic landscapes of 200 adults with de novo AML, and identified FLT3, NPM1, DNMT3a, IDH (IDH1 and IDH2), TET2, RUNX1, p53, NRAS, CEBPα and WT1 as the top 10 genes mutated at 45% frequency. 28 Other studies have highlighted the prognostic implications of each genetic abnormality alone or in the context of other known mutations. 29, 30 FLT3 MUTATIONS IN AML The FLT3 gene is located on chromosome 13q12. It encodes a type III receptor tyrosine kinase known to play a major role in the regulation of hematopoiesis. FLT3 belongs to the KIT, FMS and PDGFR family. FLT3 is expressed on the surface of normal hematopoietic stem cells; however, as these differentiate, they lose expression of this gene. 31 Activation of FLT3 requires the binding of its ligand to its extracellular domain, eventually resulting in dimerization and transphosphorylation of the A-loop. This ultimately activates multiple intracellular signaling pathways such as mitogen-activated protein kinase (MAPK) and PI3K/protein kinase B (AKT)-signals that play important roles in the proliferation, survival and differentiation of hematopoietic cells. 1, 2, 32, 33 FLT3 is overexpressed in most acute leukemias. It is mutated in more than one-third of AML cases, representing one of the most common genetic alterations. Two main types of FLT3 mutations exist. The first is the FLT3-ITD, in or near the juxta-membrane domain of the receptor, found in~23% of AML patients. The second is a missense point mutation resulting in single amino-acid substitutions that mostly involves the aspartic acid 835 of the kinase domain. In addition, less frequently seen point mutations, deletions and insertions in the codons surrounding D835 and constitutive activation of the tyrosine kinase receptor independently of the ligand, 34 as ITD mutations interfere with the negative regulatory function of the juxta-membrane region, and kinase domain point mutations involve the activation loop, resulting in the loss of the auto-inhibitory function, with subsequent constitutive activation of FLT3 kinase and its downstream proliferative signaling pathways. 35 This constitutive FLT3 signaling leads to consequent activation of STAT5, PI-3-kinase/AKT and RAS/MAPK.
PROGNOSTIC SIGNIFICANCE OF FLT3-ITD MUTATION
The presence of FLT3-ITD leads to the constitutive activation of the tyrosine kinase receptor and downstream signaling, which results in a high WBC count, a higher percentage of myeloblasts and an inferior OS. 3, 4, 29, [36] [37] [38] [39] The rate of CR in FLT3-ITD mutated AML is comparable to other AML (without FLT3-ITD), but responses are usually shorter and, subsequently, poorer responses to salvage therapies are observed. 38 Meshinchi et al. 40 showed an event-free survival (EFS) of 44% for pediatric AML cases without FLT3-ITD mutation, compared with 7% for those harboring such a mutation. The Medical Research Council AML10 and AML12 trials analyzed the outcome of 1135 AML patients based on the FLT3 mutation status. The 10-year EFS and OS were 23% and 27% in FLT3-ITD-positive, compared with 37% and 39% in FLT3-ITDnegative patients, respectively (P o 0.001). Among the total group of 311 patients who received transplant, the relapse rate at 5 years in the allograft group was 31% in the FLT3-ITD-positive patients versus 25% in FLT3-ITD-negative patients, whereas in the autograft group the relapse rate was 56% in the FLT3-ITD-positive patients versus 35% in FLT3-ITD-negative patients. 41 In addition, the German AML 96 trial evaluated the prognostic significance of FLT3 mutations in 979 AML patients. The proportion of patients 
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Abbreviations: FLT3 = FMS-like tyrosine kinase 3; GIST = gastrointestinal stromal tumor; ITD = internal tandem duplications; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasms. 10 Brunet et al. 8 addressed the influence of FLT3-ITD mutation on the outcome after allo-HCT in CR1 for patients with AML and normal karyotype. In that retrospective analysis conducted on 206 patients, the 2-year relapse incidence was higher (30% versus 16%, P = 0.006) and leukemia-free survival lower (58% versus 71%; P = 0.04) in FLT3/ITD-positive compared with FLT3/ITD-negative patients.
One particular group of patients who harbor ITD mutations, but have lost the wild-type copy of FLT3 appear to have a uniquely adverse prognosis. 42 Furthermore, several studies have demonstrated that FLT3-mutant allelic burden might also affect prognosis, but its true prognostic relevance remains to be further refined.
5,42 AML patients with high FLT3-mutant allelic ratio were more likely to respond to FLT3 inhibition compared with those with low mutant allelic ratio, likely due to higher FLT3 signaling dependency. 22 The most important factor that contributes to the variation in allelic ratio is the clonal dominance and heterogeneity of the mutation, as in high allelic ratio FLT3-ITD is present in the majority or all of the leukemic cells; however, in low allelic ratio, FLT3-ITD is present in a minor subclone within the bulk leukemic population. 43 In addition, most of the studies did not show any association of kinase domain point mutations with unfavorable prognosis. This may be the result of signaling differences between the different types of mutations. FLT3 mutations have been found to be occasionally acquired at the time of relapse in some AML patients who do not carry it at the time of initial diagnosis. 44 In these cases, they were associated with dismal outcome. Ravandi et al. 38 compared outcomes of 34 patients with normal karyotype and mutated FLT3-ITD to 69 patients with diploid cytogenetics and FLT3 wt in first relapse. The CR rate and OS from the time of relapse were inferior in patients with mutated FLT3.
MECHANISMS OF RESISTANCE TO FLT3-TKIS
There are two main mechanisms of resistance to FLT3 inhibitors. The primary resistance is due to either insensitive mutations to specific TKIs or activation of alternative signaling pathways. For instance, most of the TKIs including sorafenib have no activity against FLT3-D835 TKD mutation. Secondary resistance is the result of acquiring resistant mutations, overexpression of FLT3, autocrine FLT3 ligand stimulation or resistant mutations in the ATP binding pocket. 45 
SORAFENIB PLUS CHEMOTHERAPY AS FIRST-LINE INDUCTION FOR AML
Promising preclinical data on sorafenib activity in AML have been published in recent years. 46, 47 Thus, many clinical trials have evaluated adding sorafenib to standard chemotherapy in the first-line induction therapy in AML (Table 4) .
In FLT3-mutated AML, Uy et al. 48 reported the first prospective, single arm, phase 2 study combining sorafenib to the standard first-line induction/consolidation therapy and continuing it as maintenance in elderly (460 years). All (n = 54) patients had either FLT3-ITD (71%) or FLT3-TKD (29%) mutated AML. Following treatment, 37 (69%) patients achieved a CR or CR with incomplete blood count recovery (CRi). 48 The 30-day induction mortality was 9% with no additional deaths occurring during consolidation or maintenance. 48 No treatment-related deaths were documented. With a median follow-up of 28.3 months, 1-year OS was 62% for the FLT3-ITD and 71% for the FLT3-TKD patients. Median DFS and OS in the FLT3-ITD were 12.5 and 15.0 months, respectively, and 9.0 and 16.2 months for the FLT3-TKD group, respectively. The most commonly reported adverse events during sorafenib maintenance were grade 1 diarrhea, fatigue, transaminitis and grade 2 palmar-plantar erythrodysesthesia. The results of this study suggest that the addition of sorafenib to chemotherapy for FLT3-ITD AML significantly improves the survival of older adults compared with historical controls, (at least for patients between 60 and 70 years).
On the other hand, other studies evaluated the addition of sorafenib to conventional chemotherapy in newly diagnosed AML No pts in relapse Abbreviations: CRi = CR with incomplete blood count recovery; CRp = CR with incomplete platelet recovery; DFS = disease-free survival; EFS = event-free survival; m = month; OS = overall survival; pts = patienys; RCT = randomized controlled trial; ref = reference; S = significant; yr = year. 49 reported a randomized, placebo-controlled trial (SORAML) that addressed addition of sorafenib to standard induction-consolidation therapy in 267 newly diagnosed AML patients aged 60 years or younger. Adding sorafenib resulted in improved EFS (median of 21 versus 9 months) when compared with placebo. Similarly, 3-year EFS was significantly better with sorafenib (40% versus 22%, P = 0.013), and the relapse-free survival was 56% for the sorafenib versus 38% in the placebo group. However, no improvement in OS was observed. The 60-day mortality was 4% in both groups. A plausible explanation for these significant outcomes even in FLT3 wild-type patients is the activity of sorafenib in inhibiting other kinases such as RAF, PDGF and KIT. On the other hand, the absence of a survival advantage with sorafenib may be due to the higher proportion of allo-HCT in the placebo group (79 (59%) of 133 versus 68 (51%) of 133, respectively). In contrast, Serve et al. 50 reported an increased toxicity and early mortality without improved antileukemic efficacy when adding sorafenib to standard chemotherapy in AML patients older than 60 years in comparison to placebo. The possible explanation of this finding is the potential ability of younger patients to tolerate sorafenib better than older patients, as well as differences in disease biology with a higher proportion of secondary AML, overexpression of multidrug-resistant phenotypes and, possibly, more epigenetic changes in older patients. [51] [52] [53] Also, Ravandi et al. 54 reported a high response rate in AML patients younger than 60 years who received a sorafenib-containing induction regimen in a phase 2 single arm study (CR: 49 (79%), CR with incomplete platelet recovery: 5 (8%)), but disease relapse occurred in the majority of patients (65% of responders).
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SORAFENIB WITH OR WITHOUT CHEMOTHERAPY FOR RELAPSED AML
Several cases with relapsed FLT3-ITD AML showed extended remissions under sorafenib monotherapy. [55] [56] [57] [58] [59] [60] [61] This established the basis to evaluate the efficacy of sorafenib as monotherapy or combined with chemotherapy in relapsed FLT3-mutated AML either in the pre-or post-transplant setting (Table 5) .
Borthakur et al. 62 reported the results of a phase I study that assessed sorafenib monotherapy in two different schedules in relapsed, FLT3-mutated AML (only 16% post transplant). They showed a favorable toxicity profile and an overall response rate of 44% (CR: 6%, CR with incomplete platelet recovery: 4% and PR: 34%). Sharma et al. 63 described 16 patients treated for posttransplant relapse with sorafenib either as monotherapy (n = 8) or combined with chemotherapy (n = 8), showing discouraging responses (19% bone marrow responses), with disease progression in all cases and a median OS of only 83 days. This dismal outcome may be explained by the advanced disease status and by an interrupted sorafenib dosing schedule. Metzelder et al. 19 described more profound and sustained remissions in 29 FLT3-ITD AML patients, when sorafenib was given after allo-HCT (CR 48% and CRi 21%, complete molecular remission 24%). This may be explained by the antileukemic synergy between sorafenib and alloreactive donor cells. These findings stimulated research on the use of sorafenib as a post allo-HCT maintenance. Recently, three retrospective studies have shown favorable outcomes when using sorafenib in FLT3-mutated AML patients younger than 60 years, including in the pediatric age group, specifically in the posttransplant setting. [64] [65] [66] Tarlock et al. 64 reported the results of a retrospective study on 15 pediatric patients with FLT3/ITD+ AML, who were treated with sorafenib for post-transplant relapse (n = 9) or maintenance (n = 6). They showed an OS of 67% after a median follow-up of 21 months; however, 73% of patients experienced medically significant toxicities. In addition, a small case series by De Freitas et al. 65 on sorafenib use for post-transplant relapse FLT3/ITD+ AML in 13 relatively young patients showed an OS of 45% after 175 days follow-up. In another retrospective study by Tschan-Plessl et al., 66 sorafenib achieved high rates of durable remissions in 17 high-risk patients who underwent HCT.
SORAFENIB PLUS HYPOMETHYLATING AGENTS FOR AML
Ravandi et al. 67 combined sorafenib with azacitidine in a phase 2 study on 37 patients with FLT3-mutated AML. Half of the patients had relapsed after prior therapy, and the remaining were either primarily refractory to induction or had not received any prior 
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Abbreviations: BMR = bone marrow response; CMR = complete molecular remission; CRi = CR with incomplete blood count recovery; d = day; DFS = disease-free survival; HR = hematological remission; m = month; OS = overall survival; pts = patients; S = significant; SCT = stem cell transplantation; TTF = time to treatment failure; yr = year.
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therapy. Only seven patients had received a prior allo-HCT. The overall response was 46%, including 6 (16%) CR and 10 (27%) CRi. The median OS was 6.2 months. Not surprisingly, responders had longer OS compared with non-responders (7.8 versus 6.2 months, P = 0.01; Table 6 ). Muppidi et al. 68 combined sorafenib with decitabine in a small series of six patients with relapsed/refractory AML and demonstrated overall responses in five (83%) cases with a median survival of 155 days. Four of the five patients (80%) achieved CRi.
SORAFENIB AS MAINTENANCE THERAPY AFTER ALLO-HCT
The paradigm of maintenance therapy after allo-HCT is becoming more popular. 69 For instance, in patients with CML or Ph+ ALL, treatment with inhibitors of the BCR-ABL tyrosine kinase is widely used as prophylaxis or as therapy for minimal residual disease. 70, 71 The incorporation of sorafenib in the maintenance setting is supported by the observation that there appears to be an antileukemia synergism between sorafenib and alloreactive donor cells. In addition, chemotherapy-induced marrow aplasia leads to elevated FLT3-ligand levels that may augment on-target activity of a FLT3 inhibitor. 72 Sorafenib as a maintenance agent has been evaluated in small recent studies (Table 7) . Chen et al. 18 published the results of the first phase 1 trial of sorafenib maintenance after allo-HCT in FLT3-ITD AML patients. The study showed that sorafenib can be safely used after transplantation with a maximum tolerated dose of 400 mg twice daily. Furthermore, the study demonstrated a 1-year DFS of 85% and 1-year OS of 95% after SCT. We recently reported another series 19 on six patients who received sorafenib mostly as maintenance post-allo-HCT. All six patients were alive and in CR after a median follow-up of 16 months (range, 10-29) since first induction, and 12 months (range, 4-20) after initiation of sorafenib.
More recently, two studies on sorafenib maintenance were reported in abstract form. 21, 73 Brunner et al. 21 reported, retrospectively, the efficacy of sorafenib maintenance (versus no maintenance). The study showed that patients (n = 26) who received sorafenib had better OS compared with controls (n = 54; 83% versus 58%; P = 0.019). In multivariable analysis, sorafenib maintenance significantly improved OS (hazard ratio 0.14, P = 0.0047) and DFS (hazard ratio 0.09, P = 0.0005). Pratz et al. 73 reported the results of a prospective study of pre-and post-allogeneic transplant use of sorafenib on 28 FLT3-mutated AML patients. After a median post-transplant follow-up of 450 days (range, 107-1192), both median EFS and OS had not been reached. Fifteen of 28 patients were still on therapy without evidence of relapse at the time of publication. 73 
OTHER FLT3 INHIBITORS
In addition to sorafenib, other kinase inhibitors with inhibitory activity against FLT3 have been tested in AML (Table 8) .
Midostaurin (PKC412) was first evaluated in 20 patients with FLT3-positive relapsed/refractory AML or MDS patients not eligible for chemotherapy, and resulted in 450% reduction in peripheral blood myeloblasts in 14 (75%) patients. 15 This finding led to the launching of a randomized phase 2 trial of 95 patients with similar disease characteristics, but including both mutated and wild-type FLT3 (35 versus 60 patients). The results showed an overall response in 25 (71%) and 32 (56%) patients for FLT3-mutated and wild-type, respectively. 74 Recently, Stone et al. 75 reported the final results of a phase 3 randomized controlled trial of midostaurin in combination with daunorubicin and cytarabine as front-line treatment for 717 patients with FLT3-mutated AML o 60 years of age. Treatment consisted of daunorubicin and cytarabine induction plus midostaurin or placebo, followed by consolidation with high-dose cytarabine plus midostaurin or placebo in the case of CR, followed by maintenance midostaurin or placebo. After a median follow-up of 57 months, the median EFS and OS for the midostaurin versus placebo groups were 8 versus 3 months and 74.7 versus 26 months, respectively. Currently, there are two Abbreviations: d = day; DFS = disease-free survival; EFS = event-free survival; m = month; NR = not reached; OS = overall survival; pts = patients; S = significant; SCT = stem cell transplantation; yr = year.
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A Antar et al ongoing trials studying the efficacy of midostaurin in combination with azacitidine (NCT01093573) or decitabine (NCT01846624) in older patients with AML. Quizartinib (AC220) has been evaluated in a phase 1 study in 76 relapsed/refractory FLT3-mutated or wild type AML patients. Complete and PRs were observed in 10 (13%) and 13 (17%) patients, respectively. The median OS was 14 weeks (18 weeks for FLT3-mutated and 10 weeks for FLT3 wild type). 17 Levis et al.
76
evaluated quizartinib monotherapy in 134 patients 460 years of age with relapsed/refractory AML and showed 54% and 32% composite CR (CR+CRp+CRi) in FLT3-ITD-mutated and FLT3 wild-type cases, respectively. A phase 1/2 trial of quizartinib in combination with 5-azacitidine or low-dose cytarabine in younger patients with relapsed/refractory AML and in patients 460 years of age with previously untreated AML is currently ongoing (NCT01892371). Lestaurtinib (CEP701) has been first evaluated in a phase 1/2 study in 14 patients with relapsed/refractory FLT3-mutated AML, leading to a 50% reduction in peripheral blood blasts in 36% of patients.
14 In a phase 2 study, Knapper et al. 77 used lestaurtinib in 29 untreated patients (⩾67 years) with AML FLT3+ or wild type not considered fit for chemotherapy, and showed a bone marrow response in five and a hematological response in three patients only. Moreover, Levis et al. 78 reported a randomized trial of lestaurtinib as monotherapy or in combination with chemotherapy in relapsed/refractory FLT3-mutated AML patients, showing CR/CRi in 23 patients in the lestaurtinib arm and in 29 patients in the combination arm. No difference in OS was observed.
Crenolanib is a potent small TKI that has activity against both the FLT3-ITD and the FLT3-D835 TKD mutation. A phase II study of crenolanib on 38 relapsed/refractory AML patients (FLT3 TKI-naive: 34%; progressed on prior FLT3 TKI: 56%) showed an overall response rate of 47%. 79 Gilteritinib (ASP2215) is a potent inhibitor of FLT3 with activity against FLT3-ITD and FLT3-TKD. A phase I/II study of gilteritinib in patients with relapsed/refractory AML patients showed an overall response rate of 57%. 80 
CONCLUSION
Until recently, the therapeutic management of AML has remained unchanged for the past four decades. However, there has been significant progress in understanding the biology and genomics implications in AML. FLT3 TKIs are now showing encouraging results across a variety of AML management settings. The combination of sorafenib or other TKI with chemotherapy during induction of AML looks very promising based on at least two randomized trials, although the positive effects were not restricted to FLT3-mutated cases. Use of TKI for patients with relapsed disease can be helpful, but responses are relatively transient in most cases because of rapid acquisition of resistance. The most outstanding results were reported in the post allo-HCT setting using sorafenib as maintenance strategy in the setting of minimal residual disease negative cases. In this setting, sorafenib is well tolerated, but dose adjustments are often necessary. Finally, multiple ongoing prospective randomized trials will help to better define the place of FLT3 inhibitors in the treatment algorithm of AML. Gilteritinib for relapsed/refractory AML Phase 1/2 166 -ORR: 57% -Abbreviations: BMR = bone marrow response; CRp = CR with incomplete platelet recovery; CT = conventional therapy; d = day; EFS = event-free survival; HR = hematological remission; ind/cons/main = induction/consolidation/maintenance; m = month; ORR = overall response rate; OS = overall survival; PB = peripheral blood; PR = partial response; pts = patients; RCT = randomized controlled trial; S = significant; w = week; WT = wild type; yr = year.
